Deutsch Intern
    Cancer Research

    Hämatologische Neoplasien

    Molecular Pathogenesis of Hematological Neoplasias

    (collaboration between the Institute of Pathology, the CCC-Mainfranken, the Department of Internal Medicine II, the Clinical Research Unit 216 (CRU 216), the “Sander-Therapieeinheit Multiples Myelom”, the “Deutsche Studiengruppe Multiples Myelom” (DSMM) and the International Cancer Genome Consortium (ICGC))

    Our group is interested in the molecular pathogenesis of multiple myeloma (MM) and malignant B-cell lymphoma. Specifically, the group focuses on the clinical and molecular characterization of newly detected somatic mutations in MM and the clinical and molecular characterization of t(14;18)-negative follicular lymphoma (FL). Next generation sequencing (NGS) approaches in primary MM and FL patients such as whole exome sequencing and amplicon-sequencing for the detection of single nucleotide variants as well as the integration of gene expression and copy number data are underlying techniques to define and analyze certain molecular subgroups and to identify potential oncogenes that may serve as targets for a more personalized therapeutic approach. Subsequently, in vitro human cell line models are used to better understand the underlying biological processes that are caused by single oncogenic mutations.

    Related Publications

    Zamò A, Pischimarov J, Horn H, Ott G, Rosenwald A, Leich E. The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15041. [Epub ahead of print] PubMed PMID: 29193015.      

    Zamò A, Pischimarov J, Schlesner M, Rosenstiel P, Bomben R, Horn H, Grieb T, Nedeva T, López C, Haake A, Richter J, Trümper L, Lawerenz C, Klapper W, Möller P, Hummel M, Lenze D, Szczepanowski M, Flossbach L, Schreder M, Gattei V, Ott G, Siebert R, Rosenwald A, Leich E. Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing. Leukemia. 2017 Aug 21. doi: 10.1038/leu.2017.270. [Epub ahead of print]

    Keppler S, Weißbach S, Langer C, Knop S, Pischimarov J, Kull M, Stühmer T, Steinbrunn T, Bargou R, Einsele H, Rosenwald A, Leich E. Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma. Oncotarget. 2016 Jun 21;7(25):38762-38774. doi: 10.18632/oncotarget.9607.

    Weißbach S, Langer C, Puppe B, Nedeva T, Bach E, Kull M, Bargou R, Einsele H, Rosenwald A, Knop S, Leich E. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma. Br J Haematol. 2015 Apr;169(1):57-70. doi: 10.1111/bjh.13256. Epub 2014 Dec 17.

    Leich E, Weißbach S, Klein HU, Grieb T, Pischimarov J, Stühmer T, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Knop S, Einsele H, Bargou R, Rosenwald A.
    Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J. 2013 Feb 8;3:e102. doi: 10.1038/bcj.2012.47.

    Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E (Co-first author), Burkhardt B, Rosolowski  M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J,  Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P, MacLeod RA, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R; ICGC MMML-Seq Project.
    Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. 

    Nat Genet, 2012, 44(12):1316-20